How to use and dose ziftomenib-Komzifti

Ziftomenib - Komzifti is a drug used to treat relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). Specific guidelines need to be followed for its use and dosage to ensure the treatment is effective and safe.

First, patient selection is the key to treatment. Ziftomenib should be considered for relapsed or refractory AML only if the presence of an NPM1 mutation is confirmed. There are currently no FDA-approved tests to confirm the presence of NPM1 mutations, so caution is needed when selecting patients.

Regarding the recommended dose, the standard dose of ziftomenib is 600 mg, which should be taken orally once daily until disease progression or unacceptable toxicity occurs. Before starting ziftomenib, ensure that the white blood cell (WBC) count is at least 25 x 10⁹/L. Additionally, for patients with unconfirmed disease progression or unacceptable toxicity, a minimum of 6 months of treatment is recommended to allow for observation of a potential clinical response.

In terms of medication management, ziftomenib should be taken once a day on an empty stomach, preferably 1 hour before or 2 hours after a meal. Patients should take this medication by mouth at approximately the same time each day and swallow the capsules whole without opening, breaking, or chewing the capsules. If a dose of ziftomenib is missed, the dose should be taken as soon as possible on the same day, but at least 12 hours should elapse before the next scheduled dose. The normal taking time can be resumed the next day, but two doses cannot be taken within 12 hours.

In addition, special attention is required when using it simultaneously with acid-reducing agents. Concomitant use of proton pump inhibitors (PPIs) with ziftomenib, as well as concomitant use of histamine-2 (H2) receptor antagonists or locally acting antacids, should be avoided. If this cannot be avoided, patients should take ziftomenib 2 hours before or 10 hours after taking an H2-receptor antagonist and 2 hours before or 2 hours after taking a locally acting antacid.

Reference materials:https://www.drugs.com/komzifti.html